Financial Data and Key Metrics Changes - For the second quarter of fiscal 2026, revenue increased by 19% to $3.9 million from $3.3 million in the prior year period, reflecting strong market adoption and strategic initiatives [9] - Gross profit for the quarter totaled $3.2 million, up 29.4% from $2.5 million in the prior year period, with a gross profit percentage improvement of 660 basis points to 81.9% [9][10] - The company achieved EBITDA of $373,000 this quarter, marking the second consecutive quarter of positive EBITDA, indicating progress towards profitability [12] Business Line Data and Key Metrics Changes - Technology fees accounted for 89% of the quarter's total revenue, highlighting strong customer satisfaction and retention [9] - The next-generation cardiac monitoring device, Biocorp Pro, has seen expanded sales, contributing to the company's revenue growth and market presence [4][5] Market Data and Key Metrics Changes - Biotricity has monitored over 2 trillion heartbeats, significantly improving patient outcomes for those with atrial fibrillation, which is a primary focus for the company [8] - The company is expanding its market reach through strategic partnerships, including contracts with the VA and leading home care groups [5] Company Strategy and Development Direction - The company is focused on innovation and operational efficiency, aiming to achieve economies of scale and maintain healthy net margins similar to SaaS-like businesses [3] - Future plans include expanding the commercial team and investing profits into commercial expansion to increase market share and drive top-line growth [5][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability in the next few quarters, supported by positive cash flows and improved operating results [12][13] - The growing market interest in chronic cardiac disease management reinforces the company's confidence in its market position and future growth [14] Other Important Information - Operating expenses for the second quarter were $2.9 million, a slight increase from $2.8 million in the same period last year, with strategic investments in R&D and sales force efficiency [11] - The net loss attributable to common shareholders for the quarter was $772,000, a significant reduction from $1.6 million in the prior year period [13] Q&A Session Summary - There were no questions during the Q&A session, indicating a clear communication of the company's progress and future plans [16]